Gt biopharma to present pre-clinical data at upcoming medical conferences

Brisbane, calif., feb. 24, 2022 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® protein biologic technology platform, announced today that gt biopharma will be participating in the following upcoming medical conferences: abstract and poster presentation details are as follows: esmo targeted anticancer therapies congress (tat) (march 7-8, 2022) title: driving nk cell immunotherapy against nsclc, in the context of hypoxia, using tri-specific killer engager (trike)  abstract number:   250 session:    immunotherapy presentation type:  poster session date and time:  march 7, 9:20am (cet) (on-demand e-poster display)   location:          virtual poster board number:   17p 48th annual european society for blood and marrow transplantation (ebmt) (march 19-23, 2022) title:                  a tri-specific killer engager (trike) against b7-h3 enhances nk cell mediated killing of multiple myeloma abstract number:        as-ebmt-2022-00508 session:                       new drugs- and cell-based immune therapies presentation type:      poster session date and time:  march 19, 2022, 9:50 am (cet) location:                        prague congress center, czech republic poster board number:  p153 american association for cancer research (aacr) annual meeting (april 8-13, 2022) title: gtb-5550 (cam16-il15-camb7h3) tri-specific killer engager (trike®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas abstract number: abstract control number 3334, permanent abstract number 3435 session: clinical research excluding trials, combination immunotherapies / therapeutic antibodies presentation type: poster session date and time: april 12, 2022 1:30 pm – 5:00 pm location: ernest n.
GTBP Ratings Summary
GTBP Quant Ranking